Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

Press Releases

Year

October 13, 2020

Codiak Announces Pricing of Initial Public Offering

Additional Formats

PDF Version

October 1, 2020

Codiak Initiates Patient Dosing in Phase 1/2 Clinical Trial of exoSTING™ for the Treatment of Solid Tumors

Additional Formats

PDF Version

September 15, 2020

Codiak Initiates Subject Dosing in a Phase 1 Clinical Trial of exoIL-12™ for the Treatment of Cancer

Additional Formats

PDF Version

July 1, 2020

Codiak Names Yalonda Howze Executive Vice President, Chief Legal Officer

Additional Formats

PDF Version

June 22, 2020

Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases

Additional Formats

PDF Version

June 15, 2020

Codiak to Present New Preclinical Data on exoASO™-STAT6 and exoASO-C/EBPβ at the AACR 2020 Virtual Annual Meeting

Additional Formats

PDF Version

June 1, 2020

Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC™ Vaccine Platform in SARS-CoV-2 and HIV

Additional Formats

PDF Version

May 15, 2020

Codiak Presents New Preclinical Data Demonstrating Potential of engEx™ Engineered Exosomes to Drive New Class of Molecular Medicines

Additional Formats

PDF Version

April 29, 2020

Codiak To Present New Preclinical Data at The American Society of Gene and Cell Therapy Annual Meeting

Additional Formats

PDF Version

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2020 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter